Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer.

ABSTRACT:

Background

Limited data exist regarding the characteristics and survival outcomes of older adults with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors in routine oncology practice.

Methods

Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified 1256 patients aged ≥65 years who were diagnosed with pathologically confirmed stage I to stage IV NSCLC between 2002 and 2015 and initiated nivolumab or pembrolizumab in 2016. We examined patient characteristics and overall survival from the time of immune checkpoint inhibitor initiation through December 31, 2017.

Results

The median patient age at the time of immune checkpoint inhibitor initiatiton was 75.3 years (interquartile range, 8.5). A substantial percenta

SUBMITTER: Youn B 

PROVIDER: S-EPMC10167638 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature